Nuclera raises additional capital for eProtein™ desktop bioprinter to close Series B funding at $58M.

By nuclera_developer | July 6, 2022

Nuclera’s eProtein™ desktop bioprinter Nuclera, a biotechnology company accelerating protein expression workflows, has just raised an additional $15.5 million in Series B financing to bring the total to $58M. Nuclera will use the additional investments from Jonathan Milner and Verve Ventures to accelerate the commercial launch of the eProtein™ desktop bioprinter. To date, Nuclera has…

Read More